Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04130997 · ClinicalTrials.gov registry record · Phase 3
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
A Phase 3 study of Relapsing Multiple Sclerosis (RMS), sponsored by TG Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
- 20
- Study locations
NCT04130997 is a Phase 3 study of Relapsing Multiple Sclerosis (RMS) that is active but no longer recruiting, run by TG Therapeutics. The registered enrollment target is 1,100 participants, above the 430-participant average among 3 other Relapsing Multiple Sclerosis (RMS) trials with a reported enrollment target (156% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT04130997, a Phase 3 study of Relapsing Multiple Sclerosis (RMS), is active but no longer recruiting, sponsored by TG Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).
Conditions Studied
Interventions
- BIOLOGICAL Ublituximab
Study Locations (20)
Texas
- TG Therapeutics Investigational Trial Site - Dallas
- TG Therapeutics Investigational Trial Site - Frisco
- TG Therapeutics Investigational Trial Site - Round Rock
- TG Therapeutics Investigational Trial Site - San Antonio
Florida
- TG Therapeutics Investigational Trial Site - Miami
- TG Therapeutics Investigational Trial Site - Tampa
Ohio
- TG Therapeutics Investigational Trial Site - Columbus
- TG Therapeutics Investigational Trial Site - Westerville
California
- TG Therapeutics Investigational Trial Site - Pasadena
Colorado
- TG Therapeutics Investigational Trial Site - Denver
Illinois
- TG Therapeutics Investigational Trial Site - Northbrook
Kansas
- TG Therapeutics Investigational Trial Site - Kansas City
Michigan
- TG Therapeutics Investigational Trial Site - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2019-11-18 |
| Est. Completion | 2032-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04130997
The ClinicalTrials.gov registry entry for NCT04130997 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 430-participant average among 3 other Relapsing Multiple Sclerosis (RMS) trials with a reported enrollment target (156% higher). The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Multiple Sclerosis (RMS) appearing as the primary indexed condition, and to 1 intervention - of which Ublituximab is the first listed.
NCT04130997 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Texas, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT04130997 about?
NCT04130997 is a clinical study titled "An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis". The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).
What is the current status of trial NCT04130997?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2019-11-18. Estimated completion is 2032-05-31.
What conditions does trial NCT04130997 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis (RMS).
What interventions are being tested in trial NCT04130997?
The interventions under investigation include: Ublituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04130997?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04130997 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis (RMS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
COMPLETED · Phase 3
-
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.